Mehrdad Rabiee Rad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mehrdad Rabiee Rad has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Ghazal Ghasempour Dabaghi
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
7 shared publications Ghazal Ghasempour Dabaghi
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran
6 shared publications- Bahar Darouei
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran
5 shared publications - Reza Amani-Beni
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran
5 shared publications - Nizal Sarrafzadegan
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran
4 shared publications Bahar Darouei
Isfahan Cardiovascular Research Center Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran
3 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published byĀ WileyĀ inĀ Clinical Cardiology
- Vol.Ā 49 Ā (10)
National and Subnational Trends in Ischemic Heart Disease Burden in Iran, 1990ā2023: A Systematic Review
Background: Ischemic heart disease (IHD) remains a major cause of morbidity and mortality in Iran, but evidence is dispersed across modelābased estimates, population studies, registries, hospital surveillance, and deathāregistration data. We synthesized national and subnational evidence on IHD burden in Iran from 1990 to 2023. Methods: PubMed/MEDLINE and Scopus were searched through August 15, 2026, supplemented by Google Scholar and citation searching. Eligible studies reported incidence, prevalence, mortality, hospitalization, case fatality, postāmyocardial infarction survival, or burdenāofādisease measures. Modelābased and empirical evidence were synthesized separately, overlapping data sources were mapped, and findings were narratively synthesized because of heterogeneity. Results: Fiftyātwo reports representing 35 evidenceāsource families were included. Within GBD 2019, ageāstandardized IHD mortality declined from 285.7 to 163.6 per 100 000 between 1990 and 2019, incidence from 898.3 to 829.1, and prevalence from 6250.6 to 6198.5 per 100 000, while incident cases increased from 218 181 to 593 001. Successive GBD vintages also showed declining ageāstandardized mortality but were not directly comparable because of modeling differences. Empirical studies generally showed higher coronary event rates in men, while Isfahan surveillance and the Iranian MI Registry indicated higher shortāterm postāMI case fatality among women. Burden increased with age, provincial variation was substantial, and urbanārural patterns were inconsistent. Hospital surveillance suggested improving shortāterm outcomes. Conclusions: Successive GBD analyses estimated substantial declines in ageāstandardized IHD mortality, while absolute burden remained large and differences persisted by age, sex, geography, and data source. Stronger prevention and geographically representative surveillance are needed.
- 7 October 2026
- Published byĀ WileyĀ inĀ Clinical Cardiology
- Vol.Ā 49 Ā (10)
Open AccessNational and Subnational Trends in Ischemic Heart Disease Burden in Iran, 1990ā2023: A Systematic Review
Background: Ischemic heart disease (IHD) remains a major cause of morbidity and mortality in Iran, but evidence is dispersed across modelābased estimates, population studies, registries, hospital surveillance, and deathāregistration data. We synthesized national and subnational evidence on IHD burden in Iran from 1990 to 2023. Methods: PubMed/MEDLINE and Scopus were searched through August 15, 2026, supplemented by Google Scholar and citation searching. Eligible studies reported incidence, prevalence, mortality, hospitalization, case fatality, postāmyocardial infarction survival, or burdenāofādisease measures. Modelābased and empirical evidence were synthesized separately, overlapping data sources were mapped, and findings were narratively synthesized because of heterogeneity. Results: Fiftyātwo reports representing 35 evidenceāsource families were included. Within GBD 2019, ageāstandardized IHD mortality declined from 285.7 to 163.6 per 100 000 between 1990 and 2019, incidence from 898.3 to 829.1, and prevalence from 6250.6 to 6198.5 per 100 000, while incident cases increased from 218 181 to 593 001. Successive GBD vintages also showed declining ageāstandardized mortality but were not directly comparable because of modeling differences. Empirical studies generally showed higher coronary event rates in men, while Isfahan surveillance and the Iranian MI Registry indicated higher shortāterm postāMI case fatality among women. Burden increased with age, provincial variation was substantial, and urbanārural patterns were inconsistent. Hospital surveillance suggested improving shortāterm outcomes. Conclusions: Successive GBD analyses estimated substantial declines in ageāstandardized IHD mortality, while absolute burden remained large and differences persisted by age, sex, geography, and data source. Stronger prevention and geographically representative surveillance are needed.
- Open Access
- 12 August 2026
- Published byĀ WileyĀ inĀ Endocrinology, Diabetes & Metabolism
- Vol.Ā 9 Ā (5) , e70280
The Association Between Atherogenic Index of Plasma and Type 2 Diabetes Mellitus in a MultiāEthnic Population of Premature Coronary Artery Disease Patients: Insights From IPAD Study
Background: The atherogenic index of plasma (AIP) is a lipidābased indicator of cardiometabolic risk. We examined whether AIP is associated with prevalent type 2 diabetes mellitus (T2DM) and fasting blood sugar (FBS) in patients with premature coronary artery disease (PCAD) and explored whether this association differed across Iranian ethnic groups. Methods: We analysed 2143 patients with angiographically confirmed PCAD from the Iran Premature Coronary Artery Disease (IPAD) study, of whom 1945 had valid AIP data. CAD was defined as ā„ 50% stenosis in the left main artery or ā„ 75% stenosis in another major coronary vessel. AIP was calculated as log 10 (triglycerides/highādensity lipoprotein cholesterol). Multivariable logistic regression was used to assess the association between AIP and prevalent T2DM, and generalized linear models were used to assess the association between AIP and FBS. Results: In the fully adjusted model, including lipidālowering medication use, participants in the highest AIP quartile had higher odds of prevalent T2DM than those in the lowest quartile (OR: 1.57; 95% CI: 1.14, 2.16; p = 0.005; P for trend = 0.002). Each 1āunit increase in AIP was associated with higher odds of prevalent T2DM (OR: 1.99; 95% CI: 1.26, 3.14; p = 0.003). Higher AIP was also associated with higher FBS; compared with the lowest quartile, the highest quartile had a 15.23 mg/dL higher FBS level in the fully adjusted model (95% CI: 7.61, 22.84; p < 0.001). In exploratory ethnicityāstratified analyses, the association was most evident in the Fars subgroup, while estimates in several smaller ethnic groups were imprecise. Conclusions: Higher AIP was associated with prevalent T2DM and higher FBS in patients with PCAD. Exploratory analyses suggested possible ethnicityārelated heterogeneity, but these subgroup findings should be interpreted cautiously. Prospective studies are needed to determine whether AIP has predictive or clinical riskāstratification value in this population.
- 12 August 2026
- Published byĀ WileyĀ inĀ Endocrinology, Diabetes & Metabolism
- Vol.Ā 9 Ā (5) , e70280
Open AccessThe Association Between Atherogenic Index of Plasma and Type 2 Diabetes Mellitus in a MultiāEthnic Population of Premature Coronary Artery Disease Patients: Insights From IPAD Study
Background: The atherogenic index of plasma (AIP) is a lipidābased indicator of cardiometabolic risk. We examined whether AIP is associated with prevalent type 2 diabetes mellitus (T2DM) and fasting blood sugar (FBS) in patients with premature coronary artery disease (PCAD) and explored whether this association differed across Iranian ethnic groups. Methods: We analysed 2143 patients with angiographically confirmed PCAD from the Iran Premature Coronary Artery Disease (IPAD) study, of whom 1945 had valid AIP data. CAD was defined as ā„ 50% stenosis in the left main artery or ā„ 75% stenosis in another major coronary vessel. AIP was calculated as log 10 (triglycerides/highādensity lipoprotein cholesterol). Multivariable logistic regression was used to assess the association between AIP and prevalent T2DM, and generalized linear models were used to assess the association between AIP and FBS. Results: In the fully adjusted model, including lipidālowering medication use, participants in the highest AIP quartile had higher odds of prevalent T2DM than those in the lowest quartile (OR: 1.57; 95% CI: 1.14, 2.16; p = 0.005; P for trend = 0.002). Each 1āunit increase in AIP was associated with higher odds of prevalent T2DM (OR: 1.99; 95% CI: 1.26, 3.14; p = 0.003). Higher AIP was also associated with higher FBS; compared with the lowest quartile, the highest quartile had a 15.23 mg/dL higher FBS level in the fully adjusted model (95% CI: 7.61, 22.84; p < 0.001). In exploratory ethnicityāstratified analyses, the association was most evident in the Fars subgroup, while estimates in several smaller ethnic groups were imprecise. Conclusions: Higher AIP was associated with prevalent T2DM and higher FBS in patients with PCAD. Exploratory analyses suggested possible ethnicityārelated heterogeneity, but these subgroup findings should be interpreted cautiously. Prospective studies are needed to determine whether AIP has predictive or clinical riskāstratification value in this population.
- Open Access
- 31 January 2026
- Published byĀ BiomedpressĀ inĀ Biomedical Research and Therapy
- Vol.Ā 13 Ā (01) , 8153-8170
Stem cellāderived exosomes in the treatment of chemotherapy-induced cardiotoxicity: A systematic review of in vivo and in vitro studies
Introduction: Chemotherapy-induced cardiotoxicity (CIC) is a significant challenge in cancer treatment, with limited therapeutic options available for preventing cardiac damage. This systematic review aimed to summarize the therapeutic efficacy of stem cell-derived exosomes in CIC. Methods: PubMed/MEDLINE, Scopus, and Web of Science databases were systematically searched up to April 2024, to identify relevant in vivo and in vitro studies. Two reviewers independently screened and extracted data using a pilot-tested form. The quality of the included studies was evaluated using the SYRCLE risk of bias tool for animal studies and the QUIN (QUality IN vitro) Assessment Tool. Due to heterogeneity in models, exosome sources, isolation methods, dosing, routes, timing, and outcomes, we conducted a narrative synthesis without meta-analysis. Results: Among the 107 citations obtained from the databases, 27 were included. Exosome treatment improved cardiac function parameters, including left ventricular ejection fraction (LVEF), fractional shortening (FS), and stroke volume (SV). Exosomes were associated with favorable changes in cardiac biomarker levels, including significant reductions in troponin, creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH). Exosomes also reduced inflammation and oxidative stress markers, and ameliorated histopathological changes in cardiac tissues. They were associated with a reduction in apoptotic markers and enhanced cell survival. In addition, exosomes improved angiogenesis in daunorubicin-induced cardiac models. The available evidence suggests the beneficial effects of stem cell-derived exosomes for CIC treatment and prevention. Conclusions: Stem cell-derived exosomes demonstrate promising therapeutic effects in mitigating chemotherapy-induced cardiotoxicity by enhancing cardiac function, reducing inflammation and oxidative stress, and limiting apoptosis. These findings support the potential clinical application of exosomes as a novel, cell-free strategy for cardioprotection in cancer patients undergoing chemotherapy. Further clinical trials are warranted to confirm their efficacy and safety.
- 31 January 2026
- Published byĀ BiomedpressĀ inĀ Biomedical Research and Therapy
- Vol.Ā 13 Ā (01) , 8153-8170
Open AccessStem cellāderived exosomes in the treatment of chemotherapy-induced cardiotoxicity: A systematic review of in vivo and in vitro studies
Introduction: Chemotherapy-induced cardiotoxicity (CIC) is a significant challenge in cancer treatment, with limited therapeutic options available for preventing cardiac damage. This systematic review aimed to summarize the therapeutic efficacy of stem cell-derived exosomes in CIC. Methods: PubMed/MEDLINE, Scopus, and Web of Science databases were systematically searched up to April 2024, to identify relevant in vivo and in vitro studies. Two reviewers independently screened and extracted data using a pilot-tested form. The quality of the included studies was evaluated using the SYRCLE risk of bias tool for animal studies and the QUIN (QUality IN vitro) Assessment Tool. Due to heterogeneity in models, exosome sources, isolation methods, dosing, routes, timing, and outcomes, we conducted a narrative synthesis without meta-analysis. Results: Among the 107 citations obtained from the databases, 27 were included. Exosome treatment improved cardiac function parameters, including left ventricular ejection fraction (LVEF), fractional shortening (FS), and stroke volume (SV). Exosomes were associated with favorable changes in cardiac biomarker levels, including significant reductions in troponin, creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH). Exosomes also reduced inflammation and oxidative stress markers, and ameliorated histopathological changes in cardiac tissues. They were associated with a reduction in apoptotic markers and enhanced cell survival. In addition, exosomes improved angiogenesis in daunorubicin-induced cardiac models. The available evidence suggests the beneficial effects of stem cell-derived exosomes for CIC treatment and prevention. Conclusions: Stem cell-derived exosomes demonstrate promising therapeutic effects in mitigating chemotherapy-induced cardiotoxicity by enhancing cardiac function, reducing inflammation and oxidative stress, and limiting apoptosis. These findings support the potential clinical application of exosomes as a novel, cell-free strategy for cardioprotection in cancer patients undergoing chemotherapy. Further clinical trials are warranted to confirm their efficacy and safety.
- 21 January 2026
- Published byĀ Springer NatureĀ inĀ Journal of Diabetes & Metabolic Disorders
- Vol.Ā 25 Ā (1) , 40
Cross-sectional association of the metabolic score for insulin resistance with hypertension in multi-ethnic patients with premature coronary artery disease: the IPAD study
Purpose The relationship between the metabolic score for insulin resistance (METS-IR) and cardiometabolic risk factors in premature coronary artery disease (PCAD) is unclear. This study aimed to investigate the association between METS-IR and hypertension, as well as systolic blood pressure (SBP) and diastolic blood pressure (DBP), in patients with PCAD. Methods This cross-sectional analysis of the Iran Premature Coronary Artery Disease (IPAD) study included women aged ⤠70 and men aged ⤠60 with PCAD. Associations between METS-IR and hypertension were examined using logistic regression, and those with SBP and DBP were examined using generalized linear models. METS-IR was modeled per 1-unit increase and quartiles. Ethnicity-stratified analyses were performed in quartiles. Results are reported as odds ratios (ORs), β coefficients, and 95% confidence intervals (CIs). Results Overall, 1,688 patients were analyzed, with a mean age of 55.0 ± 7.1 years. SBP and DBP increased across the METS-IR levels (P for trend < 0.001). Continuous METS-IR was associated with a higher odds of hypertension (OR: 1.03; 95% CI: 1.02ā1.05). Compared with Q1, the highest quartile had a higher odds of hypertension (OR: 2.70; 95% CI: 1.96ā3.72; P for trend < 0.001). In ethnicity-stratified analyses, the associations were significant in the Fars (P < 0.001), Azari (P = 0.005), and Bakhtiari (P = 0.040) populations. Other ethnic groups showed imprecise estimates, owing to the small sample sizes. Conclusions METS-IR was positively associated with hypertension and higher SBP and DBP in patients with PCAD. Associations varied across ethnic groups, underscoring the need for prospective studies to define population-specific thresholds and prognostic implications.
- 21 January 2026
- Published byĀ Springer NatureĀ inĀ Journal of Diabetes & Metabolic Disorders
- Vol.Ā 25 Ā (1) , 40
Cross-sectional association of the metabolic score for insulin resistance with hypertension in multi-ethnic patients with premature coronary artery disease: the IPAD study
Purpose The relationship between the metabolic score for insulin resistance (METS-IR) and cardiometabolic risk factors in premature coronary artery disease (PCAD) is unclear. This study aimed to investigate the association between METS-IR and hypertension, as well as systolic blood pressure (SBP) and diastolic blood pressure (DBP), in patients with PCAD. Methods This cross-sectional analysis of the Iran Premature Coronary Artery Disease (IPAD) study included women aged ⤠70 and men aged ⤠60 with PCAD. Associations between METS-IR and hypertension were examined using logistic regression, and those with SBP and DBP were examined using generalized linear models. METS-IR was modeled per 1-unit increase and quartiles. Ethnicity-stratified analyses were performed in quartiles. Results are reported as odds ratios (ORs), β coefficients, and 95% confidence intervals (CIs). Results Overall, 1,688 patients were analyzed, with a mean age of 55.0 ± 7.1 years. SBP and DBP increased across the METS-IR levels (P for trend < 0.001). Continuous METS-IR was associated with a higher odds of hypertension (OR: 1.03; 95% CI: 1.02ā1.05). Compared with Q1, the highest quartile had a higher odds of hypertension (OR: 2.70; 95% CI: 1.96ā3.72; P for trend < 0.001). In ethnicity-stratified analyses, the associations were significant in the Fars (P < 0.001), Azari (P = 0.005), and Bakhtiari (P = 0.040) populations. Other ethnic groups showed imprecise estimates, owing to the small sample sizes. Conclusions METS-IR was positively associated with hypertension and higher SBP and DBP in patients with PCAD. Associations varied across ethnic groups, underscoring the need for prospective studies to define population-specific thresholds and prognostic implications.
- Open Access
- 4 April 2025
- Published byĀ Springer NatureĀ inĀ Archives of Gynecology and Obstetrics
- Vol.Ā 311 Ā (6) , 1489-1509
Thyroid function tests and serum anti-Müllerian hormone in various populations, is there any association? A systematic review and meta-analysis
Purpose This systematic review and meta-analysis aimed to evaluate the association between anti-Müllerian hormone (AMH) as a biomarker of ovarian reserve and various thyroid function tests, including thyroid-stimulating hormone (TSH), free T3 (FT3), free T4 (FT4), T3, T4, and thyroid autoantibodies, such as thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb), in various female populations. Methods A comprehensive literature search was conducted across six electronic databases and original observational studies examining the correlation between AMH levels and at least one TFT, TPOAb, or TgAb. Results Forty studies with 14,009 participants were included in the quantitative synthesis. The pooled results showed that AMH levels were not significantly correlated with TSH levels in the overall population or diverse subgroups. However, after adjusting for publication bias, a small, but significant, positive correlation was observed. Meta-regression analyses identified estradiol, FT3, and follicle-stimulating hormone (FSH) as significant moderators of AMH-TSH association in various populations. AMH was significantly positively correlated with FT3 (r = 0.177) and FT4 (r = 058), negatively correlated with T3 (r = ā 0.202) and T4 (r = ā 0.216) in the overall population, and significantly positively correlated with TPOAb in the normal population (r = 0.348). AMH levels were not significantly correlated with TgAb levels. Meta-regression revealed body mass index and FT4 as moderators in AMH-FT4 and AMH-TPOAb correlations. Conclusion These findings highlight the complex relationship between AMH and thyroid function markers with potential moderators influencing these associations. Further well-controlled longitudinal studies are required to clarify the underlying mechanisms and clinical implications of these associations across reproductive stages and metabolic profiles.
- 4 April 2025
- Published byĀ Springer NatureĀ inĀ Archives of Gynecology and Obstetrics
- Vol.Ā 311 Ā (6) , 1489-1509
Open AccessThyroid function tests and serum anti-Müllerian hormone in various populations, is there any association? A systematic review and meta-analysis
Purpose This systematic review and meta-analysis aimed to evaluate the association between anti-Müllerian hormone (AMH) as a biomarker of ovarian reserve and various thyroid function tests, including thyroid-stimulating hormone (TSH), free T3 (FT3), free T4 (FT4), T3, T4, and thyroid autoantibodies, such as thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb), in various female populations. Methods A comprehensive literature search was conducted across six electronic databases and original observational studies examining the correlation between AMH levels and at least one TFT, TPOAb, or TgAb. Results Forty studies with 14,009 participants were included in the quantitative synthesis. The pooled results showed that AMH levels were not significantly correlated with TSH levels in the overall population or diverse subgroups. However, after adjusting for publication bias, a small, but significant, positive correlation was observed. Meta-regression analyses identified estradiol, FT3, and follicle-stimulating hormone (FSH) as significant moderators of AMH-TSH association in various populations. AMH was significantly positively correlated with FT3 (r = 0.177) and FT4 (r = 058), negatively correlated with T3 (r = ā 0.202) and T4 (r = ā 0.216) in the overall population, and significantly positively correlated with TPOAb in the normal population (r = 0.348). AMH levels were not significantly correlated with TgAb levels. Meta-regression revealed body mass index and FT4 as moderators in AMH-FT4 and AMH-TPOAb correlations. Conclusion These findings highlight the complex relationship between AMH and thyroid function markers with potential moderators influencing these associations. Further well-controlled longitudinal studies are required to clarify the underlying mechanisms and clinical implications of these associations across reproductive stages and metabolic profiles.
- Open Access
- 3 April 2025
- Published byĀ Springer NatureĀ inĀ BMC Cardiovascular Disorders
- Vol.Ā 25 Ā (1) , 1-17
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Managing electrolyte abnormalities, particularly sodium and potassium, in patients with heart failure (HF) remains a concern. A novel anti-diabetic drug, sodium-glucose co-transporter-2 (SGLT2) inhibitors, has become suitable for HF patients, improving cardiovascular outcomes. Therefore, we aimed to conduct a meta-analysis to evaluate the effect of SGLT2 inhibitors on serum sodium and potassium. We systematically searched five databases, identifying randomized clinical trials (RCTs) reporting changes in serum sodium and potassium levels with SGLT2 inhibitors compared to comparator groups. Outcomes were presented as weighted mean differences (WMD) and standardized MD (SMD) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were also conducted. 13 studies were included, with 13 studies with 10,617 participants reporting on serum sodium and nine studies with 9877 participants on serum potassium. In acute HF, SGLT2 inhibitors did not significantly affect serum sodium (WMD: 1.21 mmol/L; 95% CI: ā 0.79, 3.21) or potassium levels (WMD: 0.11 mEq/L; 95% CI: ā 0.20, 0.42). Subgroup analyses suggested possible variations by follow-up duration (< 7 days vs. ā„ 30 days) and drug type, but findings remained non-significant. Sensitivity analysis using the leave-one-out method and risk of bias assessment results showed no considerable changes in the statistical significance of the pooled results. Similarly, in chronic HF, no significant differences were observed for serum sodium (WMD: 0.23 mmol/L; 95% CI: ā 0.45, 0.91) or potassium (WMD: 0.07 mEq/L; 95% CI: ā 0.29, 0.44). Sensitivity and subgroup analyses based on duration, drug type, diabetes status, renal function, or systolic blood pressure did not reveal clinically meaningful differences across all analyses. For all analyses, Eggerās test was non-significant, indicating no strong evidence of smallāstudy effects. Moreover, the trim-and-fill method combined with the funnel plot did not identify any missing studies, and the recalculated effect size remained unchanged. SGLT2 inhibitors did not significantly alter serum sodium or potassium levels in acute or chronic HF, suggesting that these drugs can be safe regarding electrolyte disturbances. Additional RCTs are warranted to enhance the robustness of evidence regarding the mechanisms and effects of SGLT2 inhibitors on serum electrolyte levels, considering variations across different types of SGLT2 inhibitors.
- 3 April 2025
- Published byĀ Springer NatureĀ inĀ BMC Cardiovascular Disorders
- Vol.Ā 25 Ā (1) , 1-17
Open AccessThe impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Managing electrolyte abnormalities, particularly sodium and potassium, in patients with heart failure (HF) remains a concern. A novel anti-diabetic drug, sodium-glucose co-transporter-2 (SGLT2) inhibitors, has become suitable for HF patients, improving cardiovascular outcomes. Therefore, we aimed to conduct a meta-analysis to evaluate the effect of SGLT2 inhibitors on serum sodium and potassium. We systematically searched five databases, identifying randomized clinical trials (RCTs) reporting changes in serum sodium and potassium levels with SGLT2 inhibitors compared to comparator groups. Outcomes were presented as weighted mean differences (WMD) and standardized MD (SMD) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were also conducted. 13 studies were included, with 13 studies with 10,617 participants reporting on serum sodium and nine studies with 9877 participants on serum potassium. In acute HF, SGLT2 inhibitors did not significantly affect serum sodium (WMD: 1.21 mmol/L; 95% CI: ā 0.79, 3.21) or potassium levels (WMD: 0.11 mEq/L; 95% CI: ā 0.20, 0.42). Subgroup analyses suggested possible variations by follow-up duration (< 7 days vs. ā„ 30 days) and drug type, but findings remained non-significant. Sensitivity analysis using the leave-one-out method and risk of bias assessment results showed no considerable changes in the statistical significance of the pooled results. Similarly, in chronic HF, no significant differences were observed for serum sodium (WMD: 0.23 mmol/L; 95% CI: ā 0.45, 0.91) or potassium (WMD: 0.07 mEq/L; 95% CI: ā 0.29, 0.44). Sensitivity and subgroup analyses based on duration, drug type, diabetes status, renal function, or systolic blood pressure did not reveal clinically meaningful differences across all analyses. For all analyses, Eggerās test was non-significant, indicating no strong evidence of smallāstudy effects. Moreover, the trim-and-fill method combined with the funnel plot did not identify any missing studies, and the recalculated effect size remained unchanged. SGLT2 inhibitors did not significantly alter serum sodium or potassium levels in acute or chronic HF, suggesting that these drugs can be safe regarding electrolyte disturbances. Additional RCTs are warranted to enhance the robustness of evidence regarding the mechanisms and effects of SGLT2 inhibitors on serum electrolyte levels, considering variations across different types of SGLT2 inhibitors.
- 12 November 2024
- Published byĀ Wolters Kluwer HealthĀ inĀ Cardiology in Review
- Vol.Ā 33 Ā (3) , 202-211
The Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Outcomes in Patients With Diabetes: A Systematic Review and Meta-Analysis
The neutrophil-to-lymphocyte ratio (NLR) has been found as a potential biomarker for acute inflammation and the prognosis of different diseases. Here, we provided a meta-analysis of studies evaluating the association of NLR with cardiovascular outcomes among patients with diabetes. We searched PubMed, Scopus, and Web of Science databases from inception to April 06, 2024, to include papers based on eligible criteria. The outcomes of interest were all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, myocardial infarction, and stroke. The pooled risk ratio (RR) and corresponding 95% confidence intervals (CI) were reported. Meta-analysis was performed using StataMP 14.0. A total of 15 studies involving 407,512 participants were included. Meta-analysis revealed that both categorical and continuous NLRs are linked to increased risk of all-cause mortality (RR = 1.68; 95% CI, 1.49ā1.88; P < 0.001 and RR = 1.03; 95% CI, 1.03ā1.03; P < 0.001, respectively) and cardiovascular mortality (RR = 2.04; 95% CI, 1.58ā2.63; P < 0.001 and RR = 1.25; 95% CI, 1.19ā1.32; P < 0.001, respectively) in patients with diabetes. However, NLR was not associated with the risk of major adverse cardiovascular events, myocardial infarction, and stroke in patients with diabetes. Subgroup analysis revealed sample size as the main source of the heterogeneity found between studies. The findings suggest NLR as a prognostic marker for mortality outcomes in patients with diabetes, providing clinicians with a noninvasive and readily available indicator for risk assessment and patient management.
- 12 November 2024
- Published byĀ Wolters Kluwer HealthĀ inĀ Cardiology in Review
- Vol.Ā 33 Ā (3) , 202-211
The Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Outcomes in Patients With Diabetes: A Systematic Review and Meta-Analysis
The neutrophil-to-lymphocyte ratio (NLR) has been found as a potential biomarker for acute inflammation and the prognosis of different diseases. Here, we provided a meta-analysis of studies evaluating the association of NLR with cardiovascular outcomes among patients with diabetes. We searched PubMed, Scopus, and Web of Science databases from inception to April 06, 2024, to include papers based on eligible criteria. The outcomes of interest were all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, myocardial infarction, and stroke. The pooled risk ratio (RR) and corresponding 95% confidence intervals (CI) were reported. Meta-analysis was performed using StataMP 14.0. A total of 15 studies involving 407,512 participants were included. Meta-analysis revealed that both categorical and continuous NLRs are linked to increased risk of all-cause mortality (RR = 1.68; 95% CI, 1.49ā1.88; P < 0.001 and RR = 1.03; 95% CI, 1.03ā1.03; P < 0.001, respectively) and cardiovascular mortality (RR = 2.04; 95% CI, 1.58ā2.63; P < 0.001 and RR = 1.25; 95% CI, 1.19ā1.32; P < 0.001, respectively) in patients with diabetes. However, NLR was not associated with the risk of major adverse cardiovascular events, myocardial infarction, and stroke in patients with diabetes. Subgroup analysis revealed sample size as the main source of the heterogeneity found between studies. The findings suggest NLR as a prognostic marker for mortality outcomes in patients with diabetes, providing clinicians with a noninvasive and readily available indicator for risk assessment and patient management.
- Open Access
- 10 September 2024
- Published byĀ Wolters Kluwer HealthĀ inĀ Annals of Medicine & Surgery
- Vol.Ā 86 Ā (11) , 6502-6506
Alterations in serum levels of calcium, vitamin D, phosphorus, and parathyroid hormone in patients with clinically confirmed familial hypercholesterolemia: a cross-sectional study
Background: Familial hypercholesterolemia (FH), an autosomal dominant disease, is associated with an increased risk of premature cardiovascular disease (CVD). This study aimed to examine the variations in serum levels of calcium, vitamin D, phosphorus, and parathyroid hormone (PTH) among FH patients, as these factors have been associated with an increased susceptibility to CVD. Materials and methods: In this cross-sectional study, the authors used data from Isfahan FH registry. The Dutch Lipid Clinic Network (DLCN) criteria was used for diagnoses of FH patients. Control group included participants with hyperlipidemia and were unlikely FH according to DLCN criteria. All biochemical parameters were measured using standard methods. Results: A total of 131 patients (mean age, 53.1 ± 12.2; male, 51.4%) were included in the analysis. Patients with FH had lower serum vitamin D levels compared with control groups in the unadjusted model (P= 0.028). The relationship between serum vitamin D and FH was not significant after adjustment for traditional risk factor (P= 0.184). No significant association was observed between FH and serum calcium (P= 0.886), phosphorus (P= 0.463), and PTH (P= 0.849). Besides, there was no significant association between LDL-C or total cholesterol and serum minerals in FH patients. Conclusion: This study found no significant changes in serum calcium, vitamin D, phosphorus, and PTH in patients with FH.
- 10 September 2024
- Published byĀ Wolters Kluwer HealthĀ inĀ Annals of Medicine & Surgery
- Vol.Ā 86 Ā (11) , 6502-6506
Open AccessAlterations in serum levels of calcium, vitamin D, phosphorus, and parathyroid hormone in patients with clinically confirmed familial hypercholesterolemia: a cross-sectional study
Background: Familial hypercholesterolemia (FH), an autosomal dominant disease, is associated with an increased risk of premature cardiovascular disease (CVD). This study aimed to examine the variations in serum levels of calcium, vitamin D, phosphorus, and parathyroid hormone (PTH) among FH patients, as these factors have been associated with an increased susceptibility to CVD. Materials and methods: In this cross-sectional study, the authors used data from Isfahan FH registry. The Dutch Lipid Clinic Network (DLCN) criteria was used for diagnoses of FH patients. Control group included participants with hyperlipidemia and were unlikely FH according to DLCN criteria. All biochemical parameters were measured using standard methods. Results: A total of 131 patients (mean age, 53.1 ± 12.2; male, 51.4%) were included in the analysis. Patients with FH had lower serum vitamin D levels compared with control groups in the unadjusted model (P= 0.028). The relationship between serum vitamin D and FH was not significant after adjustment for traditional risk factor (P= 0.184). No significant association was observed between FH and serum calcium (P= 0.886), phosphorus (P= 0.463), and PTH (P= 0.849). Besides, there was no significant association between LDL-C or total cholesterol and serum minerals in FH patients. Conclusion: This study found no significant changes in serum calcium, vitamin D, phosphorus, and PTH in patients with FH.
- Open Access
- 25 June 2024
- Published byĀ ElsevierĀ inĀ American Heart Journal Plus: Cardiology Research and Practice
- Vol.Ā 44, 100416
The role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review
- 25 June 2024
- Published byĀ ElsevierĀ inĀ American Heart Journal Plus: Cardiology Research and Practice
- Vol.Ā 44, 100416
Open AccessThe role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review
- 1 November 2022
- Published byĀ ElsevierĀ inĀ Current Problems in Cardiology
- Vol.Ā 47 Ā (11) , 101087
The Relation Between Inter Arm Blood Pressure Difference and Presence of Cardiovascular Disease: A Review of Current Findings
- 1 November 2022
- Published byĀ ElsevierĀ inĀ Current Problems in Cardiology
- Vol.Ā 47 Ā (11) , 101087
The Relation Between Inter Arm Blood Pressure Difference and Presence of Cardiovascular Disease: A Review of Current Findings